PubMed Health⌕ Search

Biomedical subjects

R S Satoskar

Publications and source records attributed to R S Satoskar.

At least 19 recordsLinked to original sources
PubMed1991

Antipyrine and doxycycline pharmacokinetics in patients with thyroid disorders.

Pathological conditions are known to affect pharmacokinetics of many drugs. Antipyrine half-life is used as a marker of liver microsomal enzyme function. Antipyrine pharmacokinetics, therefore, was investigated in 23 thyrotoxic and 11 euthyroid goitre patients. Of these, 11 thyrotoxic and 9 euthyroid goitre patients also participated in doxycycline bioavailability studies. In thyrotoxic patients, antipyrine half-life and AUCo infinity and doxycycline Cpmax and AUCo infinity were found to be reduced as compared to those of healthy euthyroid normal subjects. Following treatment of thyrotoxicosis, the antipyrine half-life and AUCo infinity returned to normal. Doxycycline AUCo infinity returned to near normal range but Cpmax did not.

Administration, Oral↗
PubMed1989

Suitability of laboratory animals for screening anti-hyperlipidemic agents.

The present study was undertaken to evaluate and compare the lipid profiles of various laboratory animals to that of human beings. The human subjects and animals included in the study were from three age groups based on key physiological states. A record of the usual dietary constituents and their daily consumption was maintained. The results indicated that the lipid profile of pigs and dogs bears similarity to that of human beings. Results also revealed that lipid profile was labile in the second group of these animals indicating that this age is suitable to bring about the required changes to produce a hyperlipidemic animal.

Animals↗
PubMed1989

Centbutindole vs trifluoperazine: a double-blind controlled clinical study in acute schizophrenia.

Twenty-nine acute schizophrenic patients were treated under double-blind conditions for six weeks with either centbutindole in a dose range of 3 mg/day to 4.5 mg/day or trifluoperazine in the dose range of 15 mg/day to 22.5 mg/day. Both drugs produced a significant improvement in initial psychopathology. No significant differences were demonstrated between the two treatment conditions.

Adult↗
PubMed1988

Effect of ascariasis and its treatment on drug absorption.

Ascariasis has been reported to impair the absorption of nutrients, vitamin A, and D-xylose, which is corrected on treatment. The effect of ascariasis and its treatment on the absorption of sulphadimidine and isoniazid has been investigated. There was no difference between drug absorption before and after the treatment or in comparison with a normal population.

Ascariasis↗
PubMed1988

Influence of menstrual cycle on antipyrine pharmacokinetics in healthy Indian female volunteers.

The effect of the menstrual cycle on antipyrine pharmacokinetics was studied in 11 normal, healthy Indian female volunteers. Antipyrine half-life, apparent volume of distribution, clearance and AUC were calculated by standard methods. Results indicated that in females, antipyrine half-life was significantly longer on day 5 as compared with that on days 15 and 21 of the menstrual cycle. It appears that hormonal changes during the menstrual cycle affect the pharmacokinetics of drugs in normal healthy females.

Adult↗
PubMed1988

Effect of iron deficiency anaemia and its treatment on the absorption and elimination of phenformin.

1. The extent of phenformin absorption and its rate of urinary excretion have been assessed in adult patients with iron deficiency anaemia, a condition which compromises gastrointestinal function. 2. Phenformin (100 mg) was administered orally to patients before treatment, three days after the start of a course of iron treatment (oral 300 mg b.d. or total intravenous iron) and at the end of 28 days, when haemoglobin was over 10 gm%. 3. No significant difference was found between mean total amounts of phenformin and 4-hydroxyphenformin excreted in urine, before treatment or after 3 or 28 days replacement therapy. It is concluded that phenformin absorption is not affected by iron deficiency. 4. In addition, iron deficiency had no significant effect on phenformin elimination half-life.

Adult↗
PubMed1987

Effect of iron deficiency anaemia and its treatment on sulphadimidine absorption.

The effect of iron deficiency anaemia and its treatment on the absorption of sulphadimidine has been investigated in adult patients. The absorption judged by total % of the dose excreted in urine and Cmax, tmax, AUC and Kabs in plasma, was not significantly different before and after iron therapy or correction of anaemia. However, sulphadimidine absorption by the anaemic patients was significantly greater than in normals.

Acetylation↗
PubMed1987

Effect of pectin and kaolin on bioavailability of co-trimoxazole suspension.

Bioavailability of co-trimoxazole suspension was determined with and without concurrent administration of pectin and kaolin in 8 volunteers. Twenty ml suspension of co-trimoxazole containing 160 mg trimethoprim (TMP) and 800 mg sulphamethoxazole (SMX) and co-trimoxazole suspension along with 20 ml of pectin-kaolin suspension were administered in a random order with 7 days interval. Plasma estimation of trimethoprim and sulphonamide was carried out at serial intervals. Area under curve (AUC) and Cmax of TMP were significantly higher when co-trimoxazole suspension alone was used. No statistically significant changes were observed in case of sulphamethoxazole. Clinical study is necessary to verify whether concurrent administration of co-trimoxazole and pectin-kaolin leads to loss of antibacterial efficacy.

Adult↗
PubMed1986

Pharmacokinetics of primaquine in patients with P. vivax malaria.

The pharmacokinetics of primaquine (PQ) and its major carboxylic acid metabolite (PQC) have been studied in seven Indian patients with P. vivax malaria following PQ 15 mg/day p.o. for 14 days. After a single oral dose on Day 1, a mean peak blood concentration of 50.7 ng/ml PQ was attained after 2.3 h, which declined monoexponentially with a half-life of 5.6 h. The mean total body clearance was 37.6 l/h and the volume of distribution was 292 l. The mean renal excretion (0-24 h) of the drug was only 0.54% of the dose and renal clearance was 0.189 l/h. Following chronic administration, none of the pharmacokinetic parameters was affected, and a steady state blood concentration of 2.5-4.2 ng/ml PQ was attained. After the first dose of PQ, PQC had a mean area under the blood concentration - time curve 11-fold higher than that of the parent drug. In contrast to the rapid distribution and elimination of PQ, the metabolite showed a longer mean residence time and accumulation in the body. The mean Cmax and AUC of the metabolite on Day 14 were 48 and 40% higher than the corresponding Day 1 values. The metabolite could not be detected in urine at any time in any patient. PQ and its metabolite did not show any accumulation in blood cells.

Adolescent↗
PubMed1986

Drug interaction between guanfacine and nonsteroidal antiinflammatory drugs in dogs.

Nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to attenuate the hypotensive actions of various antihypertensive agents. This experimental study in dogs was undertaken to find out whether NSAIDs modified the pharmacological actions of an antihypertensive drug, guanfacine. Indomethacin and enphenamic acid significantly prolonged the initial hypertensive response and blunted the subsequent hypotension produced by intravenous guanfacine. Ibuprofen and acetyl salicylic acid also interacted in a similar manner, but to a lesser extent. Phenylbutazone, on the other hand, caused a blunting of the pressor response and potentiated the hypotension following guanfacine. When indomethacin was given intracerebroventricularly, there was no interaction. These results suggest the necessity of monitoring hypertensive subjects taking guanfacine when NSAIDs are co-administered.

Animals↗
PubMed1986

Clonidine and enphenamic acid interaction study in dogs.

The drug interaction between clonidine (Cl) and enphenamic acid (En.A.), a newer non-steroidal anti-inflammatory drug (NSAID) was studied in anaesthetized dogs. Prior administration of En.A. in animals modified the blood pressure response to clonidine. Thus En.A., administered 1 hr before clonidine, potentiated the hypertensive response and blocked the subsequent hypotensive response to clonidine. Intracerebroventricular administration of En.A. did not affect the usual blood pressure response to clonidine. Similarly, this interaction was not observed in reserpinized animals and it was only partially blocked in normal dogs, treated with tolazoline. It is concluded that En.A. interferes with blood pressure responses to clonidine and that this interaction is probably of a peripheral, vascular, nature.

Adrenergic alpha-Antagonists↗